Enlivex Therapeutics
Macrophage Reprogramming Cell Therapies for Life-threatening Diseases
StartupEnlivex Therapeutics is a Ness Ziona-based startup in the Health Tech & Life Sciences sector, established in 2005. Macrophage Reprogramming Cell Therapies for Life-threatening Diseases. The company has raised a total of $74.9M across 10 funding rounds, currently at the Public stage. Enlivex Therapeutics was founded by Prof. Dror Mevorach. Key investors include Undisclosed Investor(s), Hadasit Bio-Holdings, Korea Investment Partners, among 5 total investors. The company has 11-50 employees. Core technologies: Biologicals, Cells.
With $74.9M in total funding, Enlivex Therapeutics is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQNess Ziona
- DistrictCenter District
- Last Round$15M
- Undisclosed Investor(s)
- Hadasit Bio-Holdings
- Korea Investment Partners
5 investors total
Prof. Dror MevorachFounder, Chief Scientific & Medical Officer
135 articles covered by sources including finance.yahoo.com,
www.clinicaltrialsarena.com,
www.investing.com,
newsdirect.com,
www.benzinga.com.
What does Enlivex Therapeutics do?
Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming. The company intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis, COVID-19, and other indications. The company's most advanced product candidate, Allocetra, was developed for the reprogramming of diseased macrophages in patients with sepsis or COVID-19, and has demonstrated positive safety, tolerability, and efficacy in several clinical trials. In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.
How much funding has Enlivex Therapeutics raised?
Enlivex Therapeutics has raised $74.9M in total funding across 10 rounds. The company is currently at the Public stage. Key investors include Undisclosed Investor(s), Hadasit Bio-Holdings, Korea Investment Partners.
Who founded Enlivex Therapeutics ?
Enlivex Therapeutics was founded in 2005 by Prof. Dror Mevorach (Founder, Chief Scientific & Medical Officer).
What sector is Enlivex Therapeutics in?
Enlivex Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology, Healthcare, Providers, Patients.
Where is Enlivex Therapeutics located?
Enlivex Therapeutics is based in Einstein St 14, Nes Ziona, Israel, Center District.